Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Previously, adherence and persistence to treatment have been shown to improve outcomes among patients with chronic obstructive pulmonary disease (COPD). This study aimed to evaluate adherence and persistence to single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; one inhalation, once-daily) compared with budesonide/glycopyrrolate/formoterol fumarate (BUD/GLY/FOR; two inhalations, twice-daily) among patients with COPD in the USA.
Methods: This retrospective weighted cohort study used claims data from the IQVIA PharMetrics Plus Database from October 1, 2019 to March 31, 2023, to identify patients with COPD newly initiating FF/UMEC/VI or BUD/GLY/FOR. Index date was the first pharmacy claim for FF/UMEC/VI or BUD/GLY/FOR on or after October 1, 2020. The longest follow-up period was 12 months. Inverse probability of treatment weighting was used to balance baseline characteristics between cohorts. Adherence was measured as mean proportion of days covered (PDC); the proportion of patients with PDC ≥ 0.5 and PDC ≥ 0.8 was also assessed. Persistence was assessed as time to treatment discontinuation using Kaplan-Meier rates.
Results: Overall, 8912 and 2685 patients were included in the FF/UMEC/VI and BUD/GLY/FOR cohorts, respectively. After weighting, mean age and proportion of patients with Medicare Advantage insurance was 64.62 years and 40.0% in the FF/UMEC/VI cohort and 63.96 years and 36.1% in the BUD/GLY/FOR cohort. At 6 months post-index, mean PDC was greater in the FF/UMEC/VI versus the BUD/GLY/FOR cohort (0.65 versus 0.59; P < 0.001). A significantly greater proportion of patients in the FF/UMEC/VI versus the BUD/GLY/FOR cohort had PDC ≥ 0.8 (45.6% versus 34.5%; P < 0.001) and PDC ≥ 0.5 (71.8% versus 64.3%; P < 0.001). Results were consistent at 12 months post-index. When a 30-day gap was used to define treatment discontinuation, the FF/UMEC/VI cohort had statistically significantly greater treatment persistence versus the BUD/GLY/FOR cohort at all time points.
Conclusion: In this study, patients initiating FF/UMEC/VI had significantly greater adherence and persistence to treatment than patients initiating BUD/GLY/FOR.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11787229 | PMC |
| http://dx.doi.org/10.1007/s12325-024-03055-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reimagining Outcomes: A Perspective Review of Advances in Remote Monitoring Technologies in Post-Arthroplasty Patient Care.
J Orthop Res
September 2025
Department of Kinesiology, College of Health Sciences, University of Rhode Island, Kingston, Rhode Island, USA.
Arthroplasty surgery is a common and successful end-stage intervention for advanced osteoarthritis. Yet, postoperative outcomes vary significantly among patients, leading to a plethora of measures and associated measurement approaches to monitor patient outcomes. Traditional approaches rely heavily on patient-reported outcome measures (PROMs), which are widely used, but often lack sensitivity to detect function changes (e.
View Article and Find Full Text PDFA rare bilateral renal arterial configuration featuring a right-sided crossed trajectory and left-sided type IIa branching: morphometric and embryological insights from cadaveric dissection.
Surg Radiol Anat
September 2025
Department of Anatomy, School of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.
Purpose: This study aimed to report and characterize bilateral renal artery (RA) variations observed during cadaveric dissection and to evaluate these findings in the context of embryological development and morphometric analysis.
Case Presentation: During routine anatomical dissection of an 87-year-old Caucasian male cadaver, bilateral variations in the renal arteries were identified. On the right side, two renal arteries (RRA1 and RRA2) were observed, each giving rise to presegmental and segmental branches.
Pressure injuries (PIs) remain a problem for patient safety and the sustainability of healthcare systems. Difficulties persist in their assessment, prevention and monitoring by multidisciplinary teams. International recommendations point to this problem as a priority area for resolution in terms of patient safety.
View Article and Find Full Text PDFIdentification of potential inflammation markers for outgrowth of cow's milk allergy.
PLoS One
September 2025
Laboratory of Microbiology, Wageningen University, Wageningen, The Netherlands.
Immunoglobulin E (IgE)-mediated cow's milk allergy (CMA) is an immune-mediated reaction to cow's milk (CM). Non-IgE-mediated CMA resolves in most children in the first years of life, whereas IgE-mediated CMA outgrowth is often later or not at all. The exact mechanisms underlying resolution of IgE-mediated CMA are not fully understood.
View Article and Find Full Text PDFDevelopment Track of Compliance With Dual Antiplatelet Therapy and Analysis of Potential Categories in Patients With ACS After PCI.
Rev Cardiovasc Med
August 2025
Nursing Department, The First Affiliated Hospital of Ningbo University, 315000 Ningbo, Zhejiang, China.
Background: To explore the potential categories of compliance development track of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) using growth mixture modeling (GMM) to analyze its predictive factors, providing evidence for dynamic adherence monitoring and tailored interventions.
Methods: A total of 150 patients with ACS after PCI were selected by convenience sampling. Patients were studied using Self-Efficacy for Appropriate Medication Use Scale (SEAMS), family APGAR index (APGAR), Generalized Anxiety Disorder-2 (GAD-2), and Patient Health Questionnaire-2 (PHQ-2) at baseline.